Graduated as pharmacist-economist at Semmelweis and Corvinus Universities in Budapest in 2023 and 2027, respectively. Obtained his sub auspiciis doctoral graduation in pharmaceutical chemistry at Semmelweis University in 2007, after having conducted his PhD studies partly in Belgium. Joined the company in 2007 and worked in various positions in the business development department, gaining experience in generic, value-added and original portfolio generation. Between April 2022 and the establishment of the business units in 2023 worked as Business Development Director. Head of CNS Business Unit since July 2023, having full P&L responsibility in achieving cariprazine and CNS original research and development related global strategic aims.

Dr. Erik Bogsch is the Head of the Biotechnology Business Unit at Gedeon Richter Plc (GR). The Biotechnology Business Unit covers all activities GR conducts within the biotechnology space, including development, manufacture and commercialisation of biosimilars in addition to CDMO activities. Erik has a PhD in Cell Biology, he is the author of multiple scientific publications. Erik has worked in both the food and pharmaceutical business’ in multiple geographies and has filled positions primarily in Development but also in Manufacturing and Quality. He has been working for Gedeon Richter Plc. since 2012, and has worked in various roles within the Biotechnology Business Unit, before filling the current role in 2020.

Peter Turek graduated with a degree in Pharmacy from Comenius University in Bratislava in 2004. Following graduation, he pursued advanced studies at the university, focusing on preclinical oncology compound screening. In 2006, he began his PhD studies at the Faculty of Medicine, Comenius University, culminating in a successful defense in 2010. His doctoral research focused on the metabolic syndrome and cardiovascular diseases, contributing to the understanding of these critical health challenges. From 2012 to 2014, he pursued an Executive MBA at the CEU/University of New York, earning a U.S.-accredited MBA diploma, further enhancing leadership and strategic management expertise. Peter Turek joined the company in 2004, gaining experience across sales and marketing roles. In 2010, he was promoted to General Manager of the Slovak affiliate, successfully leading operations and driving business growth. After Gedeon Richter's expansion into Western Europe in 2011, he transitioned to the Budapest headquarters as Regional Manager. He spearheaded operations with a strong focus on the WHC portfolio, contributing to regional business strategy and market penetration. In 2016 he was appointed to a global marketing leadership role in WHC, playing a pivotal role in shaping the marketing strategy. He was actively involved in selecting the right WHC license candidates, expanding the portfolio, and driving innovative marketing initiatives. He currently serves as Head of the Women’s Healthcare Business Unit, holding full P&L responsibility. He leads strategic decision-making in innovative research and development, ensuring sustainable growth and alignment with long-term corporate objectives.

Bence has been the global head of the Company's General Medicines business since July 2023. He holds a doctorate in economics and a master’s degree in pharmaceutical engineering, graduating from the Budapest University of Technology and Corvinus University of Budapest. From September 2013 he was an R+D project manager, from 2017 to 2023 head of the Global Program and Portfolio Management, from 2022 he was also responsible for the branded generic strategic pillar, and from the beginning of 2023 he was responsible for merging the traditional and branded generic strategic pillars, forming the General Medicines business. He is responsible for the strategic objectives and their achievement.